Infinity Pharmaceuticals Reports First Quarter 2022 Financial Results
– MARIO-4, the first eganelisib registration-enabling trial, in front-line metastatic triple negative breast cancer (TNBC) expected to initiate by year-end 2022 –– MARIO-P, a clinical program designed to expand eganelisib development in additional solid tumor indications, is planned to start in 3Q2022 –– Investor co...
Source: pharmiweb.com